The Coronavirus and M&A Transactions: MAE Clauses

Mar 6, 2020

Reading Time : 2 min

If a buyer claims they terminated a contract for an MAE, the court will first look to the specific language of the MAE clause. If the MAE clause carves out pandemics or epidemics from the definition of MAE, then the impact of COVID-19 clearly will not allow a buyer to terminate an agreement on the basis of the MAE. As an example, the February 20thAgreement and Plan of Merger between Morgan Stanley and E*Trade Financial Corp. specifically carves out “epidemic, pandemic or disease outbreak (including the COVID-19 virus)” from events that could result in an MAE. 1 Additionally, an impact that is this widespread across companies and industries will often be caught by a carve-out for changes in general market conditions. If there is no carve-out and it is a generic MAE clause, courts will then look to see if the buyer has shown the requisite substantial threat to the earnings potential of the target in a durationally significant manner.

Current projections of the impact of COVID-19 vary widely by country, industry and severity. As such, models to date have a variety of outcomes with the consensus suggesting potential impacts lasting through 2020. Therefore, while target companies may be adversely affected, the impact of COVID-19 to date will likely not trigger a generic MAE clause because it will be difficult to demonstrate that the impact will cause a long-term effect on financial performance, falling short of the heavy burden placed on buyers by the courts. However, the inquiry into whether an MAE has occurred is always fact-specific, and as more information about the impacts of COVID-19 are discovered, buyers will have to continually evaluate whether the impact will have a significant, long-term effect on the target company.


1 See Grace Maral Burnett, Denis Demblowski & Diane Holt, ANALYSIS: Morgan Stanley, E*Trade Merger Excludes Coronavirus, Bloomberg Law (Feb. 28, 2020, 4:25PM), (also describing epidemic and pandemic-specific MAE carve-out language used in transactions between Celgene Corp. and Bristol-Myers Squibb Co., and Aetna Inc. and CVS Health Corp.).

Share This Insight

Previous Entries

Akin Deal Diary

April 12, 2023

Read More

Akin Deal Diary

2022-12-15

On December 14, 2022, the Securities and Exchange Commission (SEC) adopted amendments regarding Rule 10b5-1 insider trading plans and related disclosures. The amendments aim to strengthen investor protections concerning insider trading and to help shareholders understand when and how insiders are trading in securities for which they may at times have material nonpublic information (MNPI). In light of these amendments, issuers should review and revise, if needed, their insider trading policies and equity grant policies.

Read more.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.